Kronos Bio (NASDAQ:KRON) Posts Quarterly Earnings Results, Misses Expectations By $0.13 EPS

Kronos Bio (NASDAQ:KRON) released its quarterly earnings results on Tuesday. The company reported ($0.43) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.13), Zacks reports. Kronos Bio had a negative net margin of 867.66% and a negative return on equity of 64.55%.

Kronos Bio Price Performance

Shares of NASDAQ:KRON traded down $0.02 during mid-day trading on Tuesday, reaching $0.93. 133,272 shares of the company traded hands, compared to its average volume of 270,226. The company’s 50 day moving average price is $0.98 and its 200-day moving average price is $0.96. The firm has a market cap of $56.26 million, a PE ratio of -0.65 and a beta of 1.79. Kronos Bio has a 52 week low of $0.69 and a 52 week high of $1.60.

About Kronos Bio

Kronos Bio, Inc, a clinical-stage biopharmaceutical company, focuses on the discovery and development of therapeutics for various cancer and other serious diseases in the United States. Its lead product candidates are KB-0742, an oral cyclin dependent kinase 9 inhibitor for the treatment of MYC-amplified solid tumors, which is in phase 2 clinical trial; and KB-9558, a core oncogenic transcription factor that drives multiple myeloma.